Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Average Recommendation of “Hold” by Brokerages

Share on StockTwits

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have earned an average recommendation of “Hold” from the eight ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and one has given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $19.80.

Several research analysts have weighed in on VNDA shares. Stifel Nicolaus reaffirmed a “hold” rating and issued a $17.00 target price on shares of Vanda Pharmaceuticals in a research report on Thursday, November 7th. ValuEngine raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Citigroup lowered Vanda Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $19.00 target price on the stock. in a research report on Thursday, November 7th. BidaskClub raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 27th. Finally, Zacks Investment Research raised Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research report on Saturday.

VNDA stock remained flat at $$15.15 during mid-day trading on Tuesday. The company’s stock had a trading volume of 935,341 shares, compared to its average volume of 557,293. Vanda Pharmaceuticals has a 12 month low of $11.83 and a 12 month high of $31.30. The business’s fifty day moving average price is $16.66 and its two-hundred day moving average price is $14.67. The stock has a market cap of $807.79 million, a PE ratio of 31.55 and a beta of 0.36.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $0.07 by $1.77. Vanda Pharmaceuticals had a return on equity of 38.90% and a net margin of 55.49%. The company had revenue of $59.49 million for the quarter, compared to analyst estimates of $58.33 million. During the same period in the prior year, the firm posted $0.13 EPS. The business’s revenue was up 21.1% compared to the same quarter last year. As a group, equities research analysts predict that Vanda Pharmaceuticals will post 2.16 EPS for the current year.

In other news, CEO Mihael Hristos Polymeropoulos sold 9,467 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $16.00, for a total transaction of $151,472.00. Following the transaction, the chief executive officer now owns 1,234,579 shares of the company’s stock, valued at approximately $19,753,264. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO James Patrick Kelly sold 4,020 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $15.94, for a total value of $64,078.80. Following the transaction, the chief financial officer now directly owns 205,726 shares in the company, valued at approximately $3,279,272.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,642 shares of company stock worth $234,100. 8.20% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. increased its holdings in shares of Vanda Pharmaceuticals by 5.2% during the 2nd quarter. BlackRock Inc. now owns 8,987,677 shares of the biopharmaceutical company’s stock valued at $126,636,000 after acquiring an additional 447,529 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Vanda Pharmaceuticals by 9.1% during the 2nd quarter. Renaissance Technologies LLC now owns 2,798,050 shares of the biopharmaceutical company’s stock valued at $39,425,000 after acquiring an additional 233,300 shares during the last quarter. Macquarie Group Ltd. increased its holdings in shares of Vanda Pharmaceuticals by 10.5% during the 2nd quarter. Macquarie Group Ltd. now owns 2,604,692 shares of the biopharmaceutical company’s stock valued at $36,700,000 after acquiring an additional 247,850 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Vanda Pharmaceuticals by 1.6% during the 2nd quarter. Invesco Ltd. now owns 1,521,183 shares of the biopharmaceutical company’s stock valued at $21,434,000 after acquiring an additional 24,525 shares during the last quarter. Finally, Stonepine Capital Management LLC increased its holdings in shares of Vanda Pharmaceuticals by 6.5% during the 2nd quarter. Stonepine Capital Management LLC now owns 1,341,943 shares of the biopharmaceutical company’s stock valued at $18,908,000 after acquiring an additional 81,655 shares during the last quarter. 99.29% of the stock is currently owned by institutional investors and hedge funds.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Featured Article: What does cost of debt say about a company’s financial health?

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.